Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1

Virology

Volumn 432, Issue 1, 2012, Pages 173-183

  Pal, Ranajit ^a   Galmin, Lindsey ^a   Pereira, Lara E ^b   Li, Bin ^b   Zhang, Jining ^b   Li, Daniel ^b   Francis, Jesse ^a   McNicholl, Janet M ^b   Weiss, Deborah E ^a   Smith, James M ^b  

^a ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Entry inhibitor; HIV 1; Microbicide; Rhesus macaques; RT Env SHIV; RT inhibitor

Indexed keywords

DAPIVIRINE; MARAVIROC; N [3 [4 (3 BENZYL 1 ETHYL 5 PYRAZOLYL) 1 PIPERIDINYLMETHYL] 4 (3 FLUOROPHENYL)CYCLOPENTYL] N METHYLVALINE; TENOFOVIR;

ANIMAL CELL; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLADISTICS; CONTROLLED STUDY; ENVELOPE GENE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; INFECTION CONTROL; MACACA; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTASE GENE; RHESUS MONKEY; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SIMIAN VIRUS; VIREMIA; VIRUS CHARACTERIZATION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS GENE; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS TRANSMISSION;

ANIMALS; DISEASE MODELS, ANIMAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MACACA MULATTA; RECOMBINATION, GENETIC; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIREMIA; VIRULENCE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; PRIMATES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84864023493     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.05.034     Document Type: Article

References (62)

1. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., Kharsany A.B., Sibeko S., Mlisana K.P., Omar Z., Gengiah T.N., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
2. Akiyama H., Ido E., Akahata W., Kuwata T., Miura T., Hayami M. Construction and in vivo infection of a new simian/human immunodeficiency virus chimera containing the reverse transcriptase gene and the 3' half of the genomic region of human immunodeficiency virus type 1. J. Gen. Virol. 2003, 84:1663-1669.
3. Ambrose Z., Boltz V., Palmer S., Coffin J.M., Hughes S.H., Kewalramani V.N. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J. Virol. 2004, 78:13553-13561.
4. Ambrose Z., Palmer S., Boltz V.F., Kearney M., Larsen K., Polacino P., Flanary L., Oswald K., Piatak M., Smedley J., Shao W., Bischofberger N., Maldarelli F., Kimata J.T., Mellors J.W., Hu S.L., Coffin J.M., Lifson J.D., KewalRamani V.N. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J. Virol. 2007, 81:12145-12155.
5. Balzarini J., De Clercq E., Uberla K. SIV/HIV-1 hybrid virus expressing the reverse transcriptase gene of HIV-1 remains sensitive to HIV-1-specific reverse transcriptase inhibitors after passage in rhesus macaques. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1997, 15:1-4.
6. Balzarini J., Pelemans H., Aquaro S., Perno C.F., Witvrouw M., Schols D., De Clercq E., Karlsson A. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol. Pharmacol. 1996, 50:394-401.
7. Barnett S.W., Srivastava I.K., Kan E., Zhou F., Goodsell A., Cristillo A.D., Ferrai M.G., Weiss D.E., Letvin N.L., Montefiori D., Pal R., Vajdy M. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. Aids 2008, 22:339-348.
8. Buckheit R.W., Hartman T.L., Watson K.M., Chung S.G., Cho E.H. Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2. Antimicrob. Agents Chemother. 2008, 52:225-236.
9. Buckheit R.W., Hartman T.L., Watson K.M., Kwon H.S., Lee S.H., Lee J.W., Kang D.W., Chung S.G., Cho E.H. The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors. Antivir. Chem. Chemother. 2007, 18:259-275.
10. Buckheit R.W., Watson K., Fliakas-Boltz V., Russell J., Loftus T.L., Osterling M.C., Turpin J.A., Pallansch L.A., White E.L., Lee J.W., Lee S.H., Oh J.W., Kwon H.S., Chung S.G., Cho E.H. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents Chemother. 2001, 45:393-400.
11. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
12. Cong M.E., Youngpairoj A.S., Zheng Q., Aung W., Mitchell J., Sweeney E., Hanson D.L., Hendry R.M., Dobard C., Heneine W., Garcia-Lerma J.G. Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. J. Virol. 2011, 85:7933-7936.
13. Cristillo A.D., Lisziewicz J., He L., Lori F., Galmin L., Trocio J.N., Unangst T., Whitman L., Hudacik L., Bakare N., Whitney S., Restrepo S., Suschak J., Ferrari M.G., Chung H.K., Kalyanaraman V.S., Markham P., Pal R. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 2007, 366:197-211.
14. Cristillo A.D., Weiss D., Hudacik L., Restrepo S., Galmin L., Suschak J., Draghia-Akli R., Markham P., Pal R. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem. Biophys. Res. Commun. 2008, 366:29-35.
15. Curtis K.A., Kennedy M.S., Luckay A., Cong M.E., Youngpairoj A.S., Zheng Q., Smith J., Hanson D., Heneine W., Owen S.M., Garcia-Lerma J.G. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis. J. Acquir. Immune Defic. Syndr. 2011, 57:355-362.
16. D'Cruz O.J., Uckun F.M. Clinical development of microbicides for the prevention of HIV infection. Curr. Pharm. Des. 2004, 10:315-336.
17. Elias C.J., Coggins C. Female-controlled methods to prevent sexual transmission of HIV. Aids 1996, 10(Suppl 3):S43-51.
18. Fletcher P., Kiselyeva Y., Wallace G., Romano J., Griffin G., Margolis L., Shattock R. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J. Virol. 2005, 79:11179-11186.
19. Garcia-Lerma J.G., Aung W., Cong M.E., Zheng Q., Youngpairoj A.S., Mitchell J., Holder A., Martin A., Kuklenyik S., Luo W., Lin C.Y., Hanson D.L., Kersh E., Pau C.P., Ray A.S., Rooney J.F., Lee W.A., Heneine W. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J. Virol. 2011, 85:6610-6617.
20. Garcia-Lerma J.G., Otten R.A., Qari S.H., Jackson E., Cong M.E., Masciotra S., Luo W., Kim C., Adams D.R., Monsour M., Lipscomb J., Johnson J.A., Delinsky D., Schinazi R.F., Janssen R., Folks T.M., Heneine W. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008, 5:e28.
21. Garg A.B., Nuttall J., Romano J. The future of HIV microbicides: challenges and opportunities. Antivir. Chem. Chemother. 2009, 19:143-150.
22. Grant R.M., Hamer D., Hope T., Johnston R., Lange J., Lederman M.M., Lieberman J., Miller C.J., Moore J.P., Mosier D.E., Richman D.D., Schooley R.T., Springer M.S., Veazey R.S., Wainberg M.A. Whither or wither microbicides?. Science 2008, 321:532-534.
23. Grant R.M., Lama J.R., Anderson P.L., McMahan V., Liu A.Y., Vargas L., Goicochea P., Casapia M., Guanira-Carranza J.V., Ramirez-Cardich M.E., Montoya-Herrera O., Fernandez T., Veloso V.G., Buchbinder S.P., Chariyalertsak S., Schechter M., Bekker L.G., Mayer K.H., Kallas E.G., Amico K.R., Mulligan K., Bushman L.R., Hance R.J., Ganoza C., Defechereux P., Postle B., Wang F., McConnell J.J., Zheng J.H., Lee J., Rooney J.F., Jaffe H.S., Martinez A.I., Burns D.N., Glidden D.V. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 2010, 363:2587-2599.
24. Harouse J.M., Gettie A., Eshetu T., Tan R.C., Bohm R., Blanchard J., Baskin G., Cheng-Mayer C. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J. Virol. 2001, 75:1990-1995.
25. Humbert M., Rasmussen R.A., Song R., Ong H., Sharma P., Chenine A.L., Kramer V.G., Siddappa N.B., Xu W., Else J.G., Novembre F.J., Strobert E., O'Neil S.P., Ruprecht R.M. SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology 2008, 5:94.
26. Jiang Y., Tian B., Agy M.B., Saifuddin M., Tsai C.C. Macaca fascicularis are highly susceptible to an RT-SHIV following intravaginal inoculation: a new model for microbicide evaluation. J. Med. Primatol. 2009, 38(Suppl 1):39-46.
27. Jochmans D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res. 2008, 134:171-185.
28. Kim C.N., Adams D.R., Bashirian S., Butera S., Folks T.M., Otten R.A. Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre-clinical interventions in non-human primates. J. Med. Primatol. 2006, 35:210-216.
29. Kish-Catalone T., Pal R., Parrish J., Rose N., Hocker L., Hudacik L., Reitz M., Gallo R., Devico A. Evaluation of -2 RANTES vaginal microbicide formulations in a nonhuman primate simian/human immunodeficiency virus (SHIV) challenge model. AIDS Res. Hum. Retroviruses 2007, 23:33-42.
30. Klasse P.J., Shattock R., Moore J.P. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu. Rev. Med. 2008, 59:455-471.
31. Klasse P.J., Shattock R.J., Moore J.P. Which topical microbicides for blocking HIV-1 transmission will work in the real world?. PLoS Med. 2006, 3.
32. Kuritzkes D.R. HIV-1 entry inhibitors: an overview. Curr. Opin. HIV AIDS 2009, 4:82-87.
33. Lederman M.M., Offord R.E., Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 2006, 6:371-382.
34. Lederman M.M., Veazey R.S., Offord R., Mosier D.E., Dufour J., Mefford M., Piatak M., Lifson J.D., Salkowitz J.R., Rodriguez B., Blauvelt A., Hartley O. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004, 306:485-487.
35. Lee E.M., Chung H.K., Livesay J., Suschak J., Finke L., Hudacik L., Galmin L., Bowen B., Markham P., Cristillo A., Pal R. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J. Virol. Methods 2010, 163:287-294.
36. Ling B., Veazey R.S., Luckay A., Penedo C., Xu K., Lifson J.D., Marx P.A. SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. Aids 2002, 16:1489-1496.
37. Livingston L.,.S.E., Mitchell J., Luo W., Paul K., Powell N., Michael Hendry R., McNicholl J., Kersh E. Hormonal synchronization of the menstrual cycles of pigtail macaques to facilitate biomedical research including modeling HIV susceptibility. J. Med. Primatol. 2011, 40:164-170.
38. Marx P.A., Spira A.I., Gettie A., Dailey P.J., Veazey R.S., Lackner A.A., Mahoney C.J., Miller C.J., Claypool L.E., Ho D.D., Alexander N.J. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 1996, 2:1084-1089.
39. McGowan I. Microbicides for HIV prevention: reality or hope?. Curr. Opin. Infect. Dis. 2010, 23:26-31.
40. Network, M.T., 2011. Microbicide trials network statement on decision to discontinue use of Tenofovir gel in VOICE, a major HIV prevention study in women. In: Microbicide Trials Network; 2011.
41. Otten R.A., Adams D.R., Kim C.N., Jackson E., Pullium J.K., Lee K., Grohskopf L.A., Monsour M., Butera S., Folks T.M. Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J. Infect. Dis. 2005, 191:164-173.
42. Owen S.M., Rudolph D.L., Wang W., Cole A.M., Waring A.J., Lal R.B., Lehrer R.I. RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 2004, 20:1157-1165.
43. Pal R., Nuttall J., Galmin L., Weiss D., Chung H.K., Romano J. Characterization of vaginal transmission of a simian human immunodeficiency virus (SHIV) encoding the reverse transcriptase gene from HIV-1 in Chinese rhesus macaques. Virology 2009, 386:102-108.
44. Pal R., Taylor B., Foulke J.S., Woodward R., Merges M., Praschunus R., Gibson A., Reitz M. Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L. J. Acquir. Immune Defic. Syndr. 2003, 33:300-307.
45. Parikh U.M., Dobard C., Sharma S., Cong M.E., Jia H., Martin A., Pau C.P., Hanson D.L., Guenthner P., Smith J., Kersh E., Garcia-Lerma J.G., Novembre F.J., Otten R., Folks T., Heneine W. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 2009, 83:10358-10365.
46. Prajapati D.G., Ramajayam R., Yadav M.R., Giridhar R. The search for potent, small molecule NNRTIs: a review. Bioorg. Med. Chem. 2009, 17:5744-5762.
47. Prevention, C.f.D.C.a., 2011. CDC trial and another major study find PrEP can reduce risk of HIV infection among heterosexuals. In: Centers for Disease Control and Prevention; 2011.
48. Ramjee G., Kamali A., McCormack S. The last decade of microbicide clinical trials in Africa: from hypothesis to facts. Aids 2010, 24(Suppl 4):S40-49.
49. Reimann K.A., Parker R.A., Seaman M.S., Beaudry K., Beddall M., Peterson L., Williams K.C., Veazey R.S., Montefiori D.C., Mascola J.R., Nabel G.J., Letvin N.L. Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J. Virol. 2005, 79:8878-8885.
50. Salazar-Gonzalez J.F., Bailes E., Pham K.T., Salazar M.G., Guffey M.B., Keele B.F., Derdeyn C.A., Farmer P., Hunter E., Allen S., Manigart O., Mulenga J., Anderson J.A., Swanstrom R., Haynes B.F., Athreya G.S., Korber B.T., Sharp P.M., Shaw G.M., Hahn B.H. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 2008, 82:3952-3970.
51. Siddappa N.B., Song R., Kramer V.G., Chenine A.L., Velu V., Ong H., Rasmussen R.A., Grisson R.D., Wood C., Zhang H., Kankasa C., Amara R.R., Else J.G., Novembre F.J., Montefiori D.C., Ruprecht R.M. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J. Virol. 2009, 83:1422-1432.
52. Sina S.T., Ren W., Cheng-Mayer C. Coreceptor use in nonhuman primate models of HIV infection. J. Transl. Med. 2011, 9(Suppl 1):S7.
53. Smith J.M., Dauner A., Li B., Srinivasan P., Mitchell J., Hendry M., Ellenberger D., Butera S., Otten R.A. Generation of a dual RT Env SHIV that is infectious in rhesus macaques. J. Med. Primatol. 2010, 39:213-223.
54. Soderberg K., Denekamp L., Nikiforow S., Sautter K., Desrosiers R.C., Alexander L. A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 2002, 76:5803-5806.
55. Trichel A.M., Rajakumar P.A., Murphey-Corb M. Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque. J. Med. Primatol. 2002, 31:171-178.
56. Tsai C.C., Emau P., Jiang Y., Agy M.B., Shattock R.J., Schmidt A., Morton W.R., Gustafson K.R., Boyd M.R. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retroviruses 2004, 20:11-18.
57. UNAIDS, 2010. UNAIDS Report on the Global AIDS Epidemic. In: UNAIDS Global Report; 2010.
58. van de Wijgert J.H., Shattock R.J. Vaginal microbicides: moving ahead after an unexpected setback. Aids 2007, 21:2369-2376.
59. Veazey R.S. Microbicide safety/efficacy studies in animals: macaques and small animal models. Curr. Opin. HIV AIDS 2008, 3:567-573.
60. Veazey R.S., Ketas T.J., Dufour J., Moroney-Rasmussen T., Green L.C., Klasse P.J., Moore J.P. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J. Infect. Dis. 2010, 202:739-744.
61. Veazey R.S., Klasse P.J., Schader S.M., Hu Q., Ketas T.J., Lu M., Marx P.A., Dufour J., Colonno R.J., Shattock R.J., Springer M.S., Moore J.P. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005, 438:99-102.
62. Veazey R.S., Ling B., Green L.C., Ribka E.P., Lifson J.D., Piatak M., Lederman M.M., Mosier D., Offord R., Hartley O. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J. Infect. Dis. 2009, 199:1525-1527.